Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease

Inclusion Criteria: A subject must meet all of the following inclusion criteria to participate in the study: * enrolled and completed HEPLISAV or Engerix-B treatment in: DV2-HBV-17 or DV2-HBV-18 and had anti-HBsAg ≥ 10 mIU/mL prior to or during DV2-HBV-18 * previously received a complete primary hepatitis B vaccine series in DV2-HBV-17 or prior to enrollment in DV2-HBV-18 * be otherwise clinically stable in the opinion of the investigator * be able and willing to provide informed consent Exclusion Criteria: A subject who meets any ONE of the following exclusion criteria is not permitted to participate in the study: * previously enrolled in DV2-HBV-18 and never obtained anti-HBsAg ≥ 10 mIU/mL * received hepatitis B vaccine off-study after enrolling in DV2-HBV-17 or DV2-HBV-18 * has known history of autoimmune disease * is unwilling or unable to comply with all the requirements of the protocol